A novel anti-EGFR monoclonal antibody inhibiting tumor cell growth by recognizing different epitopes from cetuximab

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Epidermal growth factor receptor (EGFR) is overexpressed in many epithelial tumors.
• EGFR signaling is a validated target for anti-tumor therapies.
• Existing EGFR-blocking agents demonstrate anti-tumor activity.

Purpose of the Study:

• To report a novel monoclonal antibody (mAb), A13, targeting EGFR.
• To characterize the binding and functional properties of mAb A13.
• To investigate the therapeutic potential of mAb A13, including combination therapy.

Main Methods:

• Generation of mAb A13 from mice immunized with human cervical carcinoma A431 cells.
• Binding assays (ELISAs, surface plasmon resonance) to assess EGFR affinity and epitope mapping.
• Functional assays measuring EGF-dependent EGFR tyrosine phosphorylation and in vitro tumor cell colony formation.

Main Results:

• mAb A13 binds soluble EGFR with high affinity (K(D) ≈ 5.8nM) and specifically targets EGFR-expressing tumor cells and placenta tissues.
• A13 inhibits EGF-dependent EGFR tyrosine phosphorylation in cervical and breast tumor cells.
• A13 blocks EGF binding to EGFR domain III (aa 302-503) at distinct epitopes from cetuximab, inhibiting EGFR-overexpressing lung tumor growth in vitro.

Conclusions:

• mAb A13 effectively targets EGFR and interferes with proliferation signaling by blocking EGF binding.
• mAb A13 recognizes different epitopes than cetuximab, suggesting potential for combination therapy.
• Combination therapies involving mAb A13 and cetuximab may offer enhanced anti-tumor benefits.